Akebia Therapeutics, Inc. (AKBA) 股票分析

公司概述

Akebia Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the research, development, and commercialization of novel therapeutics specifically designed for patients suffering from kidney diseases. The company's strategic focus is anchored in its product portfolio, which prominently features Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase intended for the treatment of anemia associated with chronic kidney disease. This specialized positioning places Akebia within the Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, distinguishing it from broader pharmaceutical conglomerates by its niche focus on renal health solutions. The company currently maintains a market capitalization of $377.71M, generates annual revenue of $236.20M, and employs 194 individuals to execute its operational strategy. These financial metrics indicate a mid-cap enterprise with significant revenue generation capabilities relative to its employee base, suggesting a highly efficient operational scale for a company in the specialty drug manufacturing space where high fixed costs are common.

财务健康

Akebia Therapeutics reported a revenue of $236.20M for the trailing twelve months, while its net income stood at -$5,345,000, creating a substantial disparity that reveals a cost structure dominated by research and development expenses or other non-operating costs that eride profitability despite solid top-line performance. The company generated an EBITDA of $27.27M, which serves as a critical indicator of its operational cash generation before interest, taxes, depreciation, and amortization, highlighting underlying business viability distinct from accounting net income. In terms of cash flow management, the company recorded free cash flow of $68.61M, a robust figure that signifies strong financial flexibility to fund ongoing clinical trials, expand its commercial infrastructure, or manage its debt obligations without relying on external equity financing. Margin analysis shows a gross margin of 82.9%, reflecting the high value of its proprietary drug products, contrasted sharply by an operating margin of -10.5% and a profit margin of -2.3%, indicating that while product sales are lucrative, overhead costs currently exceed operating profits. The balance sheet displays a total cash position of $184.84M against total debt of $198.78M, resulting in a debt-to-equity ratio of 609.57, which characterizes a highly leveraged financial structure typical of capital-intensive biopharmaceutical firms in growth phases. Liquidity analysis reveals a current ratio of 1.55, suggesting the company holds sufficient current assets to cover its short-term liabilities with a comfortable buffer. Return on Equity is listed as N/A due to the net loss position, while Return on Assets stands at 5.4%, demonstrating that the company is effectively utilizing its asset base to generate returns even in the absence of bottom-line net income.

估值评估

Valuation metrics for Akebia Therapeutics include a P/E Ratio (TTM) of N/A due to negative earnings, while the Forward P/E is reported at -14.84, implying that the market anticipates a path toward profitability or that current earnings do not yet reflect future revenue drivers. The Price to Book ratio is 11.46, indicating that the market values the company at a significant premium over its net book value, a common phenomenon for biotech firms with high-growth potential assets not fully captured on the balance sheet. Additional valuation context is provided by a Price to Sales ratio of 1.60 and an EV/EBITDA of 14.36, suggesting the market is pricing the company based on its revenue growth trajectory and operational cash generation rather than immediate earnings multiples. Price action over the last year has seen the stock fluctuate between a 52-Week High of $4.08 and a 52-Week Low of $1.14, providing a clear range for volatility analysis. Although the current price is not explicitly stated in the source data, the valuation metrics suggest a trading environment where the stock price is sensitive to developments in its pipeline that could shift it within this established range. The stock exhibits a Beta of 0.37, which indicates that the company's price volatility is substantially lower than the broader market, offering a less volatile profile compared to large-cap equities.

Growth & Income

Revenue growth for the company is 23.9% year-over-year, demonstrating a strong expansion in its top line, whereas earnings growth is N/A, reflecting the fact that revenue expansion has not yet translated into proportional earnings growth due to the high fixed costs inherent in the drug development lifecycle. The company does not pay dividends, as evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which means that all generated cash and earnings are retained within the business to finance clinical development and commercial scaling rather than being distributed to shareholders. This reinvestment strategy is consistent with the lifecycle of a specialty drug manufacturer where capital allocation toward R&D is prioritized to achieve future regulatory approvals and market entry. Consequently, the overall growth and income profile is characterized by significant revenue expansion and a zero-dividend policy, positioning the company as a pure-play growth investment reliant on future product commercialization success rather than current income generation.